Related Experiment Videos

The effect of critical illness and inflammation on midazolam therapy in children

Nienke J Vet1, Matthijs de Hoog, Dick Tibboel

  • 1Department of Pediatrics, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.

Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
|November 9, 2010
PubMed

Insights

Critically ill children with severe disease showed reduced midazolam clearance, indicating lower cytochrome 3A activity. However, this did not lead to decreased midazolam dose requirements in this pilot study.

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Pediatrics

Background:

  • Midazolam pharmacokinetics serve as a marker for cytochrome 3A activity.
  • Assessing drug metabolism in critically ill children is crucial for optimizing therapy.
  • Inflammation and disease severity can significantly impact drug clearance in pediatric patients.

Purpose of the Study:

  • To investigate the relationship between inflammation and disease severity and midazolam pharmacokinetics and pharmacodynamics in critically ill children.
  • To evaluate midazolam as a surrogate marker for cytochrome 3A activity in this population.

Main Methods:

  • Analysis of prospectively collected pharmacokinetic and pharmacodynamic data from a midazolam study.
  • Inclusion of 21 critically ill children requiring midazolam for sedation.
  • Utilized C-reactive protein, leukocyte count, Pediatric Logistic Organ Dysfunction (PLOD) score, and Pediatric Risk of Mortality (PRISM) score to assess inflammation and disease severity.

Main Results:

  • A significant negative correlation was found between disease severity (PLOD score) and midazolam clearance corrected for body weight (r = -0.49, p = .02).
  • Midazolam clearance was significantly lower in children with multiple organ failure (PLOD ≥ 10) compared to those without (p = .035).
  • No significant correlations were observed between inflammation markers and midazolam pharmacokinetics or pharmacodynamics.

Conclusions:

  • Increased disease severity in critically ill children is associated with reduced midazolam clearance, likely due to decreased cytochrome 3A activity.
  • Despite reduced clearance, midazolam dose requirements did not appear to decrease in relation to disease severity.
  • These findings highlight the complex interplay between critical illness, drug metabolism, and dosing in pediatric patients.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...